Literature DB >> 23113888

Who's driving anyway? Herculean efforts to identify the drivers of breast cancer.

Ryan J Hartmaier, Nolan Priedigkeit, Adrian V Lee.   

Abstract

The continuing advancement of sequencing technologies has made the systematic identification of all driving somatic events in cancer a possibility. In the June 2012 issue of Nature, five papers show some significant headway in this endeavor, each a herculean effort of genome sequencing, and transcriptome and copy number analysis resulting in data on thousands of breast cancers. Integrating these massive datasets, the authors were able to further subdivide breast cancer and identify a number of novel driver genes. While the studies represent a leap forward in describing the genomics of breast cancer, and clearly highlight the tremendous diversity between tumors, the studies only scrape the surface of molecular changes in breast tumors, with more granularity to come from the study of epigenomics, single cell sequencing, and so on. The immediate importance of the data to clinical care is currently unknown, and will depend upon detailed identification and functional analysis of driver mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23113888      PMCID: PMC4053107          DOI: 10.1186/bcr3325

Source DB:  PubMed          Journal:  Breast Cancer Res        ISSN: 1465-5411            Impact factor:   6.466


  5 in total

1.  Sequence analysis of mutations and translocations across breast cancer subtypes.

Authors:  Shantanu Banerji; Kristian Cibulskis; Claudia Rangel-Escareno; Kristin K Brown; Scott L Carter; Abbie M Frederick; Michael S Lawrence; Andrey Y Sivachenko; Carrie Sougnez; Lihua Zou; Maria L Cortes; Juan C Fernandez-Lopez; Shouyong Peng; Kristin G Ardlie; Daniel Auclair; Veronica Bautista-Piña; Fujiko Duke; Joshua Francis; Joonil Jung; Antonio Maffuz-Aziz; Robert C Onofrio; Melissa Parkin; Nam H Pho; Valeria Quintanar-Jurado; Alex H Ramos; Rosa Rebollar-Vega; Sergio Rodriguez-Cuevas; Sandra L Romero-Cordoba; Steven E Schumacher; Nicolas Stransky; Kristin M Thompson; Laura Uribe-Figueroa; Jose Baselga; Rameen Beroukhim; Kornelia Polyak; Dennis C Sgroi; Andrea L Richardson; Gerardo Jimenez-Sanchez; Eric S Lander; Stacey B Gabriel; Levi A Garraway; Todd R Golub; Jorge Melendez-Zajgla; Alex Toker; Gad Getz; Alfredo Hidalgo-Miranda; Matthew Meyerson
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

2.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

Authors:  Sohrab P Shah; Andrew Roth; Rodrigo Goya; Arusha Oloumi; Gavin Ha; Yongjun Zhao; Gulisa Turashvili; Jiarui Ding; Kane Tse; Gholamreza Haffari; Ali Bashashati; Leah M Prentice; Jaswinder Khattra; Angela Burleigh; Damian Yap; Virginie Bernard; Andrew McPherson; Karey Shumansky; Anamaria Crisan; Ryan Giuliany; Alireza Heravi-Moussavi; Jamie Rosner; Daniel Lai; Inanc Birol; Richard Varhol; Angela Tam; Noreen Dhalla; Thomas Zeng; Kevin Ma; Simon K Chan; Malachi Griffith; Annie Moradian; S-W Grace Cheng; Gregg B Morin; Peter Watson; Karen Gelmon; Stephen Chia; Suet-Feung Chin; Christina Curtis; Oscar M Rueda; Paul D Pharoah; Sambasivarao Damaraju; John Mackey; Kelly Hoon; Timothy Harkins; Vasisht Tadigotla; Mahvash Sigaroudinia; Philippe Gascard; Thea Tlsty; Joseph F Costello; Irmtraud M Meyer; Connie J Eaves; Wyeth W Wasserman; Steven Jones; David Huntsman; Martin Hirst; Carlos Caldas; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2012-04-04       Impact factor: 49.962

3.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

4.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

5.  Whole-genome analysis informs breast cancer response to aromatase inhibition.

Authors:  Matthew J Ellis; Li Ding; Dong Shen; Jingqin Luo; Vera J Suman; John W Wallis; Brian A Van Tine; Jeremy Hoog; Reece J Goiffon; Theodore C Goldstein; Sam Ng; Li Lin; Robert Crowder; Jacqueline Snider; Karla Ballman; Jason Weber; Ken Chen; Daniel C Koboldt; Cyriac Kandoth; William S Schierding; Joshua F McMichael; Christopher A Miller; Charles Lu; Christopher C Harris; Michael D McLellan; Michael C Wendl; Katherine DeSchryver; D Craig Allred; Laura Esserman; Gary Unzeitig; Julie Margenthaler; G V Babiera; P Kelly Marcom; J M Guenther; Marilyn Leitch; Kelly Hunt; John Olson; Yu Tao; Christopher A Maher; Lucinda L Fulton; Robert S Fulton; Michelle Harrison; Ben Oberkfell; Feiyu Du; Ryan Demeter; Tammi L Vickery; Adnan Elhammali; Helen Piwnica-Worms; Sandra McDonald; Mark Watson; David J Dooling; David Ota; Li-Wei Chang; Ron Bose; Timothy J Ley; David Piwnica-Worms; Joshua M Stuart; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2012-06-10       Impact factor: 49.962

  5 in total
  6 in total

Review 1.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 2.  Reprogramming strategies for the establishment of novel human cancer models.

Authors:  Ignacio Sancho-Martinez; Juan Carlos Izpisua Belmonte
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

3.  Novel insights into breast cancer genetic variance through RNA sequencing.

Authors:  Anelia Horvath; Suresh Babu Pakala; Prakriti Mudvari; Sirigiri Divijendra Natha Reddy; Kazufumi Ohshiro; Sandra Casimiro; Ricardo Pires; Suzanne A W Fuqua; Masakazu Toi; Luis Costa; Sujit S Nair; Saraswati Sukumar; Rakesh Kumar
Journal:  Sci Rep       Date:  2013       Impact factor: 4.996

4.  Establishment of human iPSC-based models for the study and targeting of glioma initiating cells.

Authors:  Ignacio Sancho-Martinez; Emmanuel Nivet; Yun Xia; Tomoaki Hishida; Aitor Aguirre; Alejandro Ocampo; Li Ma; Robert Morey; Marie N Krause; Andreas Zembrzycki; Olaf Ansorge; Eric Vazquez-Ferrer; Ilir Dubova; Pradeep Reddy; David Lam; Yuriko Hishida; Min-Zu Wu; Concepcion Rodriguez Esteban; Dennis O'Leary; Geoffrey M Wahl; Inder M Verma; Louise C Laurent; Juan Carlos Izpisua Belmonte
Journal:  Nat Commun       Date:  2016-02-22       Impact factor: 14.919

5.  A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies SHARPIN as a breast cancer metastasis gene and prognostic biomarker.

Authors:  Victor M Bii; Dustin T Rae; Grant D Trobridge
Journal:  Oncotarget       Date:  2015-11-24

Review 6.  Therapeutic landscape in mutational triple negative breast cancer.

Authors:  Yaqin Shi; Juan Jin; Wenfei Ji; Xiaoxiang Guan
Journal:  Mol Cancer       Date:  2018-07-14       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.